Enrylaze is a cancer medicine used in adults and children aged one month and older to treat acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), cancers of white blood cells called lymphoblasts. It is used in combination with other medicines in patients who have developed hypersensitivity (allergic reactions) or silent inactivation to E. coli-derived asparaginase, another cancer medicine. Silent inactivation means development of antibodies (proteins) that reduce the effectiveness of asparaginase without resulting in apparent allergy symptoms. Enrylaze contains the active substance crisantaspase.
Therapeutic Indication
### Therapeutic indication Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Therapeutic Area (MeSH)
N/AATC Code
L01XX02
ATC Item
asparaginase
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| crisantaspase | N/A | Asparaginase Erwinia chrysanthemi |
EMA Name
Enrylaze
Medicine Name
Enrylaze
Aliases
N/ANo risk management plan link.
